Astellas at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Astellas takes part in 2 sessions at ESMO 2026 in Madrid, and exhibits at Booth 1054. Its program centres on stomach and gastroesophageal junction cancers that carry the CLDN18.2 marker. It also covers why the first treatment choice matters in advanced prostate cancer and urothelial cancer of the bladder and urinary tract.
| Organization | ESMO 2026 Attendance |
|---|---|
Astellas Tokyo, Japan | |
Japanese pharmaceutical company whose oncology medicines include enzalutamide, enfortumab vedotin and zolbetuximab. | Booth Exhibiting at Booth 1054 Satellite Fri Oct 23 18:15–19:45 Astellas - Solving the puzzle: Optimising practice in CLDN18.2+ gastric/GEJ adenocarcinoma Gastrointestinal cancers Satellite Sun Oct 25 13:00–14:30 |
Instantly find 20 buyers from Astellas
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction